Questions over dual use and whether menthol flavours would attract at-risk groups led the start of the long-awaited Food and Drug Administration (FDA) hearing for Philip Morris International (PMI)’s modified risk claim for its IQOS heated-tobacco product
Sign up to access to our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
